RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Abiraterone Significantly Extends Survival in mCRPC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 16
OP 17
DO 10.1177/155989771436012
UL http://mdc.sagepub.com/content/14/36/16.abstract
AB Abiraterone acetate as therapy for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) improved overall survival (OS) compared with placebo in the final OS analysis of the phase 3 COU-AA-302 clinical trial. This article discusses data from more than 4 years of follow-up from the international, randomized, double-blind, placebo-controlled COU-AA-302. Abiraterone is an orally available inhibitor of the CYP17 enzyme complex, a key regulator of androgen synthesis.